Healthy Skepticism International News
IFPMA
July 1996
Vol 14 Issue 7/8 Follow-up: IFPMA rulings: "Unsurpassed" dishonesty. The IFPMA's decision on our complaint about Parke-Davis' promotion of Ponstan (mefenamic acid) for paediatric use in Pakistan. The claims were "unsurpassed efficacy compared to acetominophen (paracetamol) in fever control", "faster antipyretic action", "prolonged duration of action", "better tolerance" etc. Parke-Davis had earlier agreed to remove the claim of "better tolerance" but continued to endorse its other claims. The IFPMA ruling was that no breach of the Code had occurred and "The company points out that the phrase 'Unsurpassed efficacy ...' does not mean superiority, it means equivalence." Our letter in reply protests.
Comments
Our members can see and make comments on this page.
